Blood cancer patients who receive a type of anti-cancer therapy should continue to take the drug while having COVID-19 ...

Janus kinase (JAK) inhibitors, including ruxolitinib cream and abrocitinib, demonstrate strong efficacy in atopic dermatitis ...

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

During a live event, Catherine J. Lee, MD, MS, discussed the mechanism of action of approved therapies for chronic ...

Tagrisso is associated with positive outcomes among patients with unresectable stage 3 EGFR-mutant non-small cell lung cancer ...

After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...

The approval came on the bases of the results from the phase 3 CABINET study. The study compared cabozantinib to a placebo in ...

The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients ...

There were a number of notable developments for patients with kidney cancer at the symposium, Dr. Emre Yekedüz explained.

OS for osimertinib vs placebo was 58.8 vs 54 months at the latest analysis of the phase 3 LAURA trial, according to ...

This article introduces the role of kinases in neurodegenerative diseases, the development of kinase inhibitors for the ...